NCT05715840View on ClinicalTrials.gov

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

368

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

May 31, 2026

Conditions
Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
Interventions
DRUG

SG001 injection

360 mg，Q3W，IV infusion

DRUG

Paclitaxel

175 mg/m\^2，Q3W，IV infusion

DRUG

Cisplatin

50 mg/m\^2，Q3W，IV infusion

DRUG

Carboplatin

AUC=5，Q3W，IV infusion

DRUG

Bevacizumab injection

15 mg/kg，Q3W，IV infusion

DRUG

SG001 placebo

Q3W，IV infusion

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT05715840 - Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) | Biotech Hunter | Biotech Hunter